M. Hauben, D. Madigan, C. M. Gerrits, L. Walsh, and E. P. Van-puijenbroek, The role of data mining in pharmacovigilance, Expert Opin Drug Saf, vol.4, issue.5, pp.929-977, 2005.

R. H. Meyboom, A. C. Egberts, I. R. Edwards, Y. A. Hekster, F. H. De-koning et al., Principles of signal detection in pharmacovigilance, Drug Saf, vol.16, issue.6, pp.355-65, 1997.

G. Bouvenot and M. Vray, Essais cliniques : Théorie, pratique et critique. 4ème édition, 2006.

K. Martin, B. Bégaud, P. Latry, G. Miremont-salamé, A. Fourrier et al., Differences between clinical trials and postmarketing use, Br J Clin Pharmacol, vol.57, issue.1, pp.86-92, 2004.

R. C. Zink, O. Marchenko, M. Sanchez-kam, H. Ma, and Q. Jiang, Sources of Safety Data and Statistical Strategies for Design and Analysis: Clinical Trials, Ther Innov Regul Sci, vol.52, issue.2, pp.141-58, 2018.

, Report of CIOMS Working Group X. Evidence Synthesis and Meta-Analysis for Drug Safety, Council for International Organizations of Medical Sciences (CIOMS), 2016.

J. A. Berlin, B. J. Crowe, E. Whalen, H. A. Xia, C. E. Koro et al., Meta-analysis of clinical trial safety data in a drug development program: answers to frequently asked questions, Clin Trials Lond Engl, vol.10, issue.1, pp.20-31, 2013.

P. W. Lane, Meta-analysis of incidence of rare events, Stat Methods Med Res

, Apr, vol.22, issue.2, pp.117-149

T. Greco, A. Zangrillo, G. Biondi-zoccai, and G. Landoni, Meta-analysis: pitfalls and hints, Heart Lung Vessels, vol.5, issue.4, pp.219-244, 2013.

, Thalidomide in Mann's Pharmacovigilance, Mann's Pharmacovigilance, 2014.

, History of pharmacovigilance, Mann's Pharmacovigilance, 2014.

E. Poluzzi, E. Raschi, C. Piccinni, F. Fabrizio-de-ponti, P. Tubert-bitter et al., medicine/data-mining-techniques-in-pharmacovigilance-analysis-of-the-publiclyaccessible-fda-adverse-event-re 13. World Health Organization, Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS), vol.7, pp.323-332, 1998.

A. Pariente, F. Gregoire, A. Fourrier-reglat, F. Haramburu, and N. Moore, Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias, Drug Saf, vol.30, issue.10, pp.891-899, 2007.

F. Haramburu, B. Bégaud, and Y. Moride, Temporal trends in spontaneous reporting of unlabelled adverse drug reactions, Br J Clin Pharmacol, vol.44, issue.3, pp.299-301, 1997.

Y. Moride, F. Haramburu, A. A. Requejo, and B. Bégaud, Under-reporting of adverse drug reactions in general practice, Br J Clin Pharmacol, vol.43, issue.2, pp.177-81, 1997.

R. Izem, M. Sanchez-kam, H. Ma, R. Zink, and Y. Zhao, Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance, Ther Innov Regul Sci, vol.52, issue.2, pp.159-69, 2018.

A. Bate, M. Lindquist, and I. R. Edwards, The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database, Fundam Clin Pharmacol, vol.22, issue.2, pp.127-167, 2008.

L. Hazell and S. Shakir, Under-reporting of adverse drug reactions : a systematic review, Drug Saf, vol.29, issue.5, pp.385-96, 2006.

E. P. Van-puijenbroek, A. Bate, H. Leufkens, M. Lindquist, R. Orre et al., A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions, Pharmacoepidemiol Drug Saf, vol.11, issue.1, pp.3-10, 2002.

J. Montastruc, A. Sommet, H. Bagheri, and M. Lapeyre-mestre, Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database, Br J Clin Pharmacol, vol.72, issue.6, pp.905-913, 2011.

A. Wisniewski, A. Bate, C. Bousquet, A. Brueckner, G. Candore et al., Good Signal Detection Practices: Evidence from IMI PROTECT, Drug Saf, vol.39, pp.469-90, 2016.

G. Candore, K. Juhlin, K. Manlik, B. Thakrar, N. Quarcoo et al., Comparison of statistical signal detection methods within and across spontaneous reporting databases, Drug Saf, vol.38, issue.6, pp.577-87, 2015.

K. J. Rothman, S. Lanes, and S. T. Sacks, The reporting odds ratio and its advantages over the proportional reporting ratio, Pharmacoepidemiol Drug Saf, vol.13, issue.8, pp.519-542, 2004.

S. J. Evans, P. C. Waller, and S. Davis, Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports, Pharmacoepidemiol Drug Saf, vol.10, issue.6, pp.483-489, 2001.

A. European-medicines, Guideline on the use of Statistical Signal Detection Methods in the EudraVigilance Data Analysis System, 2006.

A. Szarfman, S. G. Machado, O. Neill, and R. T. , Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database, Drug Saf, vol.25, issue.6, pp.381-92, 2002.

A. Bate, M. Lindquist, I. R. Edwards, S. Olsson, R. Orre et al., A Bayesian neural network method for adverse drug reaction signal generation, Eur J Clin Pharmacol, vol.54, issue.4, pp.315-336, 1998.

A. European-medicines, Screening for adverse reactions in EudraVigilance, 2016.

. Dec,

J. S. Almenoff, E. N. Pattishall, T. G. Gibbs, W. Dumouchel, S. Evans et al., Novel statistical tools for monitoring the safety of marketed drugs, Clin Pharmacol Ther, vol.82, issue.2, pp.157-66, 2007.

M. Maciá-martínez, F. J. De-abajo, G. Roberts, J. Slattery, B. Thakrar et al., An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies, Drug Saf, vol.39, issue.1, pp.29-43, 2016.

J. Mahé, E. P. De-campaigno, A. Chené, J. Montastruc, F. Despas et al.,

, Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase, Br J Clin Pharmacol, vol.84, issue.10, pp.2373-83, 2018.

E. Patras-de-campaigno, E. Bondon-guitton, G. Laurent, and F. Montastruc,

J. Montastruc and M. Lapeyre-mestre, Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics, Br J Clin Pharmacol, vol.83, issue.7, pp.1544-55, 2017.

T. Nguyen, A. Pariente, J. Montastruc, M. Lapeyre-mestre, and V. Rousseau,

O. Rascol, An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders, Br J Clin Pharmacol, vol.83, issue.3, pp.612-634, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01406529

E. Raschi, E. Poluzzi, F. Salvo, A. Pariente, F. De-ponti et al., Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems, Nutr Metab Cardiovasc Dis NMCD, vol.28, issue.6, pp.533-575, 2018.

K. B. Hoffman, M. Dimbil, C. B. Erdman, N. P. Tatonetti, and B. M. Overstreet, The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from, Drug Saf, vol.37, issue.4, pp.283-94, 2006.

A. Pariente, P. Avillach, F. Salvo, F. Thiessard, G. Miremont-salamé et al.,

A. Reglat, Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. Drug Saf, vol.35, pp.855-64, 2012.

. Uppsala-monitoring-centre, , 2018.

, The Council for International. Organizations of Medical Sciences. Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for their Use, 2000.

, World Health Organization. Safety of Medicines -A Guide to Detecting and Reporting Adverse Drug Reactions -Why Health Professionals Need to Take Action, 2002.

J. Faillie, Indication bias or protopathic bias?, Br J Clin Pharmacol, vol.80, issue.4, pp.779-80, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01983159

J. C. Weber, K. D. Rainsford, G. D. Velo, and . Eds, Side-effects of antiinflammatory drugs, advances in inflammation research, 1984.

B. Grundmark, L. Holmberg, H. Garmo, and B. Zethelius, Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area, Eur J Clin Pharmacol, vol.70, issue.5, pp.627-662, 2014.

M. Arnaud, F. Salvo, I. Ahmed, P. Robinson, N. Moore et al., A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases, Drug Saf, vol.39, issue.3, pp.251-60, 2016.

F. Montastruc, F. Salvo, M. Arnaud, B. Bégaud, and A. Pariente, Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase(®), Drug Saf, vol.39, issue.7, pp.689-96, 2016.

J. Cohen, Statistical power analysis for the behavioral sciences, vol.567

K. Linnet, Evaluation of regression procedures for methods comparison studies, Clin Chem, vol.39, issue.3, pp.424-456, 1993.

R. D. Cook, Detection of Influential Observation in Linear Regression, Technometrics, vol.19, issue.1, pp.15-23, 1977.

U. S. , Suicidality in Children and Adolescents Being Treated With Antidepressant Medications, 2004.

, Information for healthcare professionals: Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate), 2007.

. September,

S. Leucht, A. Cipriani, L. Spineli, D. Mavridis, D. Orey et al.,

, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, Lancet Lond Engl, vol.382, issue.9896, pp.951-62, 2013.

S. C. Palmer, D. Mavridis, E. Navarese, J. C. Craig, M. Tonelli et al., Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis, Lancet Lond Engl, vol.385, issue.9982, pp.2047-56, 2015.

A. Cipriani, X. Zhou, D. Giovane, C. Hetrick, S. E. Qin et al., Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis, Lancet Lond Engl, vol.388, pp.881-90, 2016.

J. A. López-lópez, J. Sterne, H. Thom, J. Higgins, A. D. Hingorani et al., Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. The BMJ [Internet, vol.359, 2017.

S. C. Palmer, D. Mavridis, A. Nicolucci, D. W. Johnson, M. Tonelli et al., Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis, JAMA, vol.316, issue.3, pp.313-337, 2016.